Skip to main content

Table 5 Results of studies on benzene exposure and specific type of myeloid malignancy*

From: The importance of evaluating specific myeloid malignancies in epidemiological studies of environmental carcinogens

Reference

Exposure category

AML

CML

MDS

MPN

Myeloid leukemia

Point estimate

95% CI

Point estimate

95% CI

Point estimate

95% CI

Point estimate

95% CI

Point estimate

95% CI

Adegoke 2003 [37]

>  15 yrs

2.9

1.2–7.0

5

1.8–13.9

      

Albin 2003 [38]

High exp

    

0.95

0.54–1.7

    

Blair 2001 [39]

High exp.

1.1

0.3–3.9

0

2.6

0.7–9.7

    

Bjork 2001a [40]

Exposed

  

1.2

0.66–2.3

      

Bonzini 2019 [41]

20+ years

2.05

0.66–6.36

1.34

0.17–8.80

    

1.98

0.82–4.75

Collins 2015 [42]

25+ ppm-yrs

1.39

0.17–5.03

  

25.1

0.63–139.6

  

1.93

0.53–4.94

Copley 2017 [43]

> 12 ppm

    

3.47

1.65–7.28

    

Costantini 2008 [44]

M/H exp

0.9

0.4–2.3

        

Divine 1999 [45]

Exposed

1.29

0.79–1.99

1.05

0.54–1.83

      

Divine 2000 [46]

Exposed

1.92

1.10–3.13

0.94

0.34–2.05

      

Guenel 2002 [47]

> 5.5 unit-yrs

2.4

0.7–8.5

1.2

0.1–11.4

      

Huebner 2009 [48]

Exposed

1.07

0.84–1.36

1.01

0.67–1.47

1.64

0.78–3.01

    

Ireland 1997† [49]

≥ 72 ppm-mo

4.5

0.1–25.3

        

Kirkeleit 2008 [50]

Exposed

2.89

1.25–6.67

1.44

0.19–10.7

      

Linet 2015 [51]

Exposed

2.1

0.9–5.2

2.5

0.8–10.7

1.9-∞

  

2.2

1.1–4.6

McCraw 1985 [52]

Exposed

3.94

1.72–7.88

1.21

0.02–6.96

      

Poynter 2017 [53]

≥ 5 years

1.77

1.19–2.63

  

2.10

1.35–3.28

    

Rhomberg 2016 [54]

≥ 80.11 ppm-yrs (0 lag)

10.11

3.71–22.01

        
 

≥ 74.55 ppm-yrs (10 yr lag)

10.76

3.95–23.43

        
 

≥ 73.53 ppm-yrs (20 yr lag)

6.37

1.31–18.61

        

Rushton 2014 [55]

> 2.93 ppm-yrs

1.39

0.68–2.85

        
 

>  0.259 ppm

1.90

0.86–4.18

        
 

>  28 yrs

1.70

0.75–3.87

        
 

> 0.413 max ppm

1.65

0.75–3.63

        

Saberi Hosnijeh 2013 [33]

Exposed

1.52

0.78–1.81

1.97

0.75–5.19

    

1.60

0.95–2.69

Sathiakumar 1995 [56]

Exposed

2.8

1.1–7.3

1.6

0.43–5.9

    

2.1

1.0–4.3

Satin 1996 [57]

Exposed

0.63

0.30–1.15

0.84

0.31–1.84

      

Schnatter 2012 [58]

> 2.93 ppm-yrs

  

2.20

0.63–7.68

4.33

1.31–14.3

1.79

0.68–4.74

  
 

> 0.259 ppm

  

0.91

0.25–3.28

3.12

0.90–10.8

1.17

0.39–3.52

  
 

> 28 yrs

  

1.42

0.35–5.67

1.74

0.61–4.99

0.82

0.25–2.73

  
 

> 0.413 max ppm

  

0.59

0.15–2.37

2.81

0.79–10.1

0.85

0.28–2.61

  

Stenehjem 2015 [59]

≥0.124 ppm-yrs

4.85

0.88–27.0

      

2.24δ§

0.65–7.71

 

≥13 yrs

0.97

0.08–11.0

      

1.47§

0.37–5.88

 

>  0.013 ppm

3.47

0.63–19.0

      

1.66§

0.48–5.74

Strom 2005 [60]

High exp

    

2.05

1.20–3.51

    

Talibov 2014 [34]

> 13.6 ppm-yrs

0.80

0.56–1.15

        

Teras 2019 [61]

≥1.49 μg/m3

0.98

0.68–1.42

  

1.28

0.86–1.92

  

0.89

0.67–1.19

Wong 1993 [62]

Exposed

(marine)

0.74

0.24–1.73

1.33

0.36–3.4

      
 

Exposed (land)

1.51

0.80–2.57

0.26

0.01–1.43

      

Wong 2001a [63]

Exposed

1.47

0.76–2.57

1.31

0.43–3.07

      

Wong 2001b [64]

Exposed

0.45

0.01–2.53

1.96

0.24–7.07

      

Wong 2010 [65]

Exposed

1.43

1.05–1.93

        
  1. * Only studies reporting results on specific myeloid malignancy types are reported. †Study reports acute-nonlymphocytic leukemia (ANLL). ‡RR estimate is for MDS/AML combined. §Myeloid malignancies including MDS. Four cases of MDS were reported, and MDS was not analyzed separately
  2. Abbreviations: NA Not available; M/H Medium/high; exp. Exposure; mo Months; ppm Parts per million; yrs. Years;